Benitez Hidalgo Olga, Martinez Garcia M Fernanda, Bescos Cabestre Agustin, Juarez Gimenez Juan Carlos, Gironella Mesa Mercedes, Bosch Albareda Francesc
Hematology Department Experimental Hematology Vall d'Hebron Institute of Oncology (VHIO) Hospital Universitari Vall d'Hebron Vall d'Hebron Barcelona Hospital Campus Barcelona Spain.
Medicine Department Universitat Autònoma de Barcelona Barcelona Spain.
Clin Case Rep. 2022 May 23;10(5):e05848. doi: 10.1002/ccr3.5848. eCollection 2022 May.
Extended half-life FIX (EHL-FIX) concentrates have been developed with the purpose of reducing the frequency of infusions in patients with severe or moderate hemophilia B. We describe the case of a 63-year-old patient with severe hemophilia B (sHB) treated with FIX-Fc fusion protein (rFIXFc) who underwent neurosurgery.
延长半衰期的凝血因子IX(EHL-FIX)浓缩剂已被研发出来,目的是减少重度或中度B型血友病患者的输注频率。我们描述了一例63岁重度B型血友病(sHB)患者的病例,该患者接受了FIX-Fc融合蛋白(rFIXFc)治疗并接受了神经外科手术。